Galderma ZO Skin Health Deal Puts Growth Off to Year Two

Galderma is paying a $1.5 billion enterprise value for ZO Skin Health, and its own announcement ties the brand's renewed growth to a date: "beginning in the second year following closing." The release says Galderma "plans to increase commercial investment during the first year of ownership to strengthen the foundation for renewed growth beginning in the second year following closing." The price works out to about 4.5 times ZO's trailing sales, by TradeFlock calculation.

What Galderma Agreed to Pay for ZO Skin Health

Galderma, the Swiss dermatology group listed on the SIX exchange, announced the deal on Wednesday, October 14, 2026, as an ad hoc announcement under Swiss listing rules. It will buy 100% of ZO Skin Health, based in Irvine, California, from shareholders including funds managed by Blackstone Tactical Opportunities and the Obagi family.

The deal is all cash, "subject to customary adjustments," and will be funded through "a combination of existing cash reserves and bank financing," the release says. Galderma expects it to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary conditions. The announcement confirmed a Reuters exclusive published Tuesday, October 13, which said Blackstone acquired ZO through its tactical opportunities fund in 2020 and that L'Oréal owns a 20% stake in Galderma.

ZO recorded net sales of about $330 million in the twelve months to June 2026, according to the release. It sells more than 40 products through more than 16,500 physician, medical spa and online accounts in more than 40 countries.

Galderma's Own Words Point to a Growth Reset

The release does not give ZO's recent growth rate, but its language points in one direction. Galderma chief executive Flemming Ornskov said the company sees "significant opportunities to reignite its growth through investment in innovation and commercial reach." The release also sets out a timeline: higher spending in year one, then "renewed growth beginning in the second year following closing."

Blackstone's quote describes the period since that 2020 investment. Senior managing director Shary Moalemzadeh said Blackstone partnered with the company "during an important period of growth when the company more than doubled its revenue." Read together, the statements describe a business that grew fast under Blackstone and that its buyer now expects to rebuild before it grows again. That is TradeFlock's reading; neither company has published ZO's year-over-year sales trend.

The profit guidance fits the same pattern. Galderma expects the deal to be "slightly dilutive to the Group's Core EBITDA margin in 2027" and to reach a margin "broadly comparable with the Group's average from 2028 onwards." It expects the deal to be neutral to Core EPS in the first full year after closing.

How the Price Compares With Galderma's Own Numbers

Galderma reported first half 2026 results on Thursday, July 23. Net sales were $3.134 billion, up 24.6% at constant currency, and Core EBITDA was $802 million, a 25.6% margin. Dermatological Skincare, the unit that will house ZO next to Cetaphil and Alastin, posted $848 million of first half sales, up 16.4% at constant currency. Net leverage fell to 1.2x at the end of June.

Measure	Figure
ZO enterprise value	$1.5 billion
ZO net sales, 12 months to June 2026	about $330 million
EV to trailing sales (TradeFlock calculation)	about 4.5x
Galderma first half 2026 Core EBITDA	$802 million
Price as a multiple of Galderma first half Core EBITDA (TradeFlock calculation)	about 1.9x
ZO trailing sales vs Galderma first half net sales (TradeFlock calculation)	about 10.5%

The release does not disclose ZO's EBITDA, so no EBITDA multiple can be worked out for the deal. The comparison in the last row mixes a twelve month figure with a six month one and is meant only to show scale. Galderma says the deal fits its commitment to "a solid investment grade credit rating."

Why Galderma Wants a Second Professional Brand

Galderma says ZO's daily, retinol and acid based regimens complement Alastin's peptide based products for use before and after procedures. The release says ZO sells through physician, medical spa and online accounts, while Galderma calls itself a "partner of choice for dermatologists, plastic surgeons and aesthetic professionals." Spending on beauty and wellness has become a battleground for both brands and retailers, as TradeFlock has reported.

The deal is smaller than the drug deals TradeFlock has tracked this month, such as Viatris's purchase of Pacira, and it puts ZO next to Alastin in Galderma's professional skincare lineup. Lazard and JP Morgan advised Galderma, with Ropes & Gray as legal adviser. Raymond James and Citi advised ZO, with Weil, Gotshal & Manges and Paul Weiss as counsel to ZO and Blackstone.

The open question is how long the reset takes. Galderma has put a date on it: growth from year two. Investors can check that against the Dermatological Skincare line once ZO's sales start showing up in Galderma's reports.

Cover photo: A smear of white skincare cream on a plain surface, by Jana Kukebal on Pexels, used under the Pexels License.